Logix Communications

Logix Biosciences is a biopharmaceutical company dedicated to the discovery and development of precision therapeutics and companion diagnostics for allergy relief, infectious diseases, and antimicrobial resistance. The company's lead program, LGX 242, is a synthetic small molecule currently in pre-clinical development for the treatment of allergies, with potential applications in asthma and the prevention of MRSA in wound care. Logix Biosciences leverages a unique technology platform that includes active ingredients derived from medical-grade manuka honey, known for its antibacterial and angiogenic properties. In 2024, the company entered into a strategic know-how agreement with the Mayo Clinic to accelerate its drug development pipeline and address significant unmet medical needs.